Highlights PeptiDream Inc.

Equities

4587

JP3836750004

Market Closed - Japan Exchange Other stock markets 11:30:00 13/05/2024 am IST			5-day change	1st Jan Change
1,954 ^JPY	-0.43%		-2.08%	+31.42%

07/05	Jefferies Adjusts PeptiDream’s Price Target to 1,900 Yen From 1,400 Yen, Keeps at Hold	MT
30/04	Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	30/04	CI
PeptiDream Inc. Announces Expansion of Peptide Discovery Collaboration with Novartis Pharma AG	30/04	CI
PeptiDream to Partake in Bristol Myers' Tender Offer for All RayzeBio Shares	15/02	MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024	14/02	CI
PeptiDream Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/02	CI
PeptiDream Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	09/11	CI
Peptidream Announces Update on PDL1 Program Partnered with Bristol-Myers Squibb Company	26/23/26	CI
PeptiDream Inc. Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide- Radioisotope Drug Conjugates	20/23/20	CI
RayzeBio, Inc. has completed an IPO in the amount of $310.9968 million.	14/23/14	CI
PeptiDream Unit Pays 4 Billion Yen Contingent Consideration for AMYViD Indication Change; Shares Down 3%	11/23/11	MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	09/23/09	CI
PeptiDream Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	09/23/09	CI
Astellas Pharma Inc. and PeptiDream Inc. Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders	25/23/25	CI
PeptiDream Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023	11/23/11	CI
PeptiDream Inc. Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate	22/23/22	CI
Ono Enters into A Drug Discovery Collaboration Agreement with Peptidream to Discover and Develop Macrocyclic Constrained Peptide Therapeutics	14/23/14	CI
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	14/23/14	CI
PeptiDream Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
Eli Lilly Teams Up With Japan's PeptiDream for Discovery of New Peptide Drug Conjugates	27/22/27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PeptiDream Inc.

Equities

4587

JP3836750004

Highlights

Filters